Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | BCL3 | P20749 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10132761 | 0.85 | FFAR1 (0.51) | FFAR1NPC1ALDH1A1HRH3RAB9A | |
| SCHEMBL11917483 | 0.79 | SRC (0.63) | FFAR1NPC1ALDH1A1RAB9AROCK2 | |
| SCHEMBL10132780 | 0.78 | HPGD (0.62) | NPC1ALDH1A1HRH3RAB9ASMN1; SMN2 | |
| SCHEMBL254621 | 0.76 | SRC (0.70) | FFAR1ROCK2ROCK1 | |
| SCHEMBL8161181 | 0.75 | BCL3 (0.84) | BCL3ALDH1A1KMT2A | |
| SCHEMBL12782442 | 0.74 | SRC (0.59) | FFAR1ROCK2ROCK1 | |
| SCHEMBL10132920 | 0.74 | HRH3 (0.62) | NPC1ALDH1A1HRH3RAB9ASMN1; SMN2 | |
| SCHEMBL11917542 | 0.73 | TUBB4A (0.80) | FFAR1NPC1HTTRAB9AROCK2 | |
| SCHEMBL23928240 | 0.73 | LTA4H (0.60) | NPC1ALDH1A1HRH3RAB9ASMN1; SMN2 | |
| SCHEMBL10132960 | 0.73 | KDM1A (0.52) | NPC1HRH3RAB9ASMN1; SMN2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124605-B2 | Compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124605-B2 | Compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | OAKTREE FUND ADMINISTRATION, LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | OAKTREE FUND ADMINISTRATION, LLC | 2009-06-11 | — | — | US | disclosed |
| WO-2009009041-A2 | COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | MAP3K6, MAP3K4, MAP3K3 | FFAR1 4167/4885BCL3 1206/4885NPC1 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.